The strategic partnership with Clinigene International establishes a “reliable, trustworthy, and cost-efficient global footprint for clinical pharmacology services,” giving both companies an opportunity to “engage pharmaceutical clients strategically and accelerate first-in-human to proof-of-concept clinical development,” Spaulding said.
While Clinigene can offer preclinical development services through its sister-company Syngene, Spaulding will cover the FIH/SAD/MAD (first in human/ single ascending dose/multiple ascending dose) end.
Clinigene also provides DDI (drug-drug interaction) and proof-of-concept services, backed up by its central and bioanalytical laboratories.
“With Clinigene’s expertise and cost-effective approach to BA/BE [bioavailability.bioequivalence] and Spaulding’s market-leading TQT [cardiac risk] study and Cardiac Core Lab expertise, our clients are able to easily structure a program for their compound that delivers high-value while keeping the molecule knowledge experts involved throughout the entire early clinical development of the compound,” said Randol Spaulding, chief executive officer of Spaulding Clinical.
